Compositions and methods for delivering GLP-1 agonists (metabolix)
A pH-neutral, rapidly disintegrating oral composition with entero-hepatic recycling agents and permeation enhancers addresses the low bioavailability of GLP-1 agonists, enabling effective oral delivery and synergistic weight loss through a GLP-1 agonist and SGLT-2 antagonist combination.
WO2025166413A1 Publication Date: 2025-08-14IX BIOPHARMA PTE LTD
8 Cites 1 Cited by
Patent Information
- Application Number
- PCT/AU2025/050085
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-05
- Filing Date
- 2025-02-05
- Publication Date
- 2025-08-14
AI Technical Summary
Technical Problem
Existing GLP-1 agonists like semaglutide have low oral bioavailability and are susceptible to gastric acid and digestive enzymes, making them unsuitable for effective oral administration for weight management.
Method used
A composition comprising a GLP-1 agonist and a SGLT-2 receptor antagonist, formulated as a rapidly disintegrating solid dosage form, using entero-hepatic recycling agents and permeation enhancers to protect against stomach acidity and enhance absorption, with a pH-neutral formulation to stabilize the active ingredients.
Benefits of technology
The composition achieves enhanced bioavailability and efficacy of GLP-1 agonists, allowing for effective oral delivery and synergistic weight loss effects comparable to subcutaneous administration.
✦ Generated by Eureka AI based on patent content.
Abstract
A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.
Need to check novelty before this filing date? Find Prior Art